LIGAND PHARMACEUTICALS (LGND) Stock News

NASDAQ:LGND - Nasdaq - US53220K5048 - Common Stock - Currency: USD

146.32 +3.92 (+2.75%)

After market: 146.32 0 (0%)

LGND Latest News, Press Relases and Analysis

All

Press Releases

17 hours ago - By: Chartmill

Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth

17 hours ago - By: The Motley Fool

Ligand (LGND) Q2 Revenue Jumps 15%

19 hours ago - By: Ligand Pharmaceuticals

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

21 hours ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

7 days ago - By: Orchestra BioMed Holdings, Inc. - Mentions: OBIO MDT

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

15 days ago - By: Ligand Pharmaceuticals

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

a month ago - By: Benzinga - Mentions: CHRO PTHS

Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease

a month ago - By: Ligand Pharmaceuticals

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

a month ago - By: Ligand Pharmaceuticals

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

2 months ago - By: Ligand Pharmaceuticals

Ligand Announces 2025 Investor Day in New York City

3 months ago - By: Ligand Pharmaceuticals

Ligand Reports First Quarter 2025 Financial Results

3 months ago - By: Ligand Pharmaceuticals

Ligand to Participate in May Investor Conferences

4 months ago - By: Ligand Pharmaceuticals

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

4 months ago - By: Ligand Pharmaceuticals

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

4 months ago - By: Yahoo Finance - Mentions: CHRO NVDA AAPL

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

5 months ago - By: Ligand Pharmaceuticals

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

6 months ago - By: Ligand Pharmaceuticals Incorporated

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

6 months ago - By: Ligand Pharmaceuticals Incorporated

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

7 months ago - By: Investor's Business Daily - Mentions: MRNA ALNY EXEL CORT ...

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

8 months ago - By: Ligand Pharmaceuticals Incorporated

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

8 months ago - By: Investor's Business Daily - Mentions: ACLX GILD JNJ

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

9 months ago - By: Ligand Pharmaceuticals Incorporated

Ligand to Present at Stifel 2024 Healthcare Conference

9 months ago - By: Ligand Pharmaceuticals Incorporated

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

9 months ago - By: Ligand Pharmaceuticals Incorporated